Cytokinetics Inc 2024年度报告

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.Yes☑No☐ Indicate by check mark whether the Registrant has submitted electronically Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☑No☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filer☑Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that preparedor issued its audit report.☑ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included inthe filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☑ The approximate aggregate market value of voting and non-voting common stock held by non-affiliates of the registrant was$5.6billionas of June28, 2024.(A) (A)Excludes 13.7 million shares of common stock held by directors and executive officers, and any stockholders whose ownership exceeds ten percent of the sharesoutstanding, at June 28, 2024. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct orcause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant. As of February 26, 2025, the number of shares outstanding of the Registrant’s common stock, par value $0.001 per share, was118,410,689shares. DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s Proxy Statement for its 2024 Annual Meeting of Stockholders to be filed with the Securities and ExchangeCommission, no later than 120 days after the end of the fiscal year, are incorporated by reference into Part III of this Annual Report on Form 10-K. CYTOKINETICS, INCORPORATEDFORM 10-KYEAR ENDED DECEMBER 31, 2024INDEX Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART IIMarket for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases Item 5.of Equity Securities37Item 6.[Reserved]38Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations39Item 7A.Quantitative and Qualitative Disclosures About Market Risk50Item 8.Financial Statements and Supplementary Data51Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure83Item 9A.Controls and Procedures83Item 9B.Other Information86Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections86 PART IIIDirectors, Executive Officers and Corporate Governance Item 10.87Item 11.Executive Compensation87Item 12.SecurityOwnership of Certain Beneficial Owners and Management and RelatedStockholder Matters87Item 13.Certain Relationships and Related Transactions, and Director Independence87Item 14.Principal Accountant Fees and Services87 PART IVExhibits and Financial Statement Schedules GLOSSARY OF TERMS Unless the context requires otherwise, references to “Cytokinetics,” “the Company,” “we,” “us” or “our” inthis Form 10-K (defined below) refer to Cytokinetics, Incorporated and its subsidiaries. References to “Notes” inthis Form 10-K are to the Notes to the Consolidated Financial Statements in this Form 10-K. We als